New Zealand markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
227.11-2.57 (-1.12%)
At close: 04:00PM EST
226.81 -0.30 (-0.13%)
After hours: 07:59PM EST

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100

Full-time employees3,400

Key executives

NameTitlePayExercisedYear born
Dr. Jeffrey Marc Leiden M.D., Ph.D.Exec. Chairman3.14M36.36M1956
Dr. Reshma Kewalramani FASN, M.D.CEO, Pres & Director3.86M506.93k1973
Mr. Charles F. Wagner Jr.Exec. VP & CFO1.71MN/A1968
Mr. Stuart A. Arbuckle B.Sc.Exec. VP & COO2.03M2.07M1966
Dr. David M. AltshulerExec. VP of Global Research & Chief Scientific Officer1.81M2.03M1965
Ms. Kristen AmbroseChief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. ServicesN/AN/A1976
Mr. Mike TirozziSVP and Chief Information & Data OfficerN/AN/AN/A
Mr. Michael PartridgeSr. VP of Investor RelationsN/AN/AN/A
Mr. Damian W. Wilmot Esq.Sr. VP, Chief Risk and Compliance OfficerN/AN/A1976
Ms. Joy LiuSr. VP & Gen. CounselN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Corporate governance

Vertex Pharmaceuticals Incorporated’s ISS governance QualityScore as of 26 September 2021 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.